Analysis of the Occurrence of Diseases Following Gastrectomy for Early Gastric Cancer: a Nationwide Claims Study

Ho Seok Seo, Yewon Na, Jaehun Jung

Division of Gastrointestinal Surgery, Department of Surgery, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
Artificial Intelligence and Big-Data Convergence Center, Gil Medical Center, Gachon University College of Medicine and Science, Incheon, Korea
Graduate School of Public Health, Seoul National University, Seoul, Korea
Departement of Preventive Medicine, Gachon University College of Medicine, Incheon, Korea

ABSTRACT

Purpose: Various changes in nutrition, metabolism, immunity, and psychological status occur through multiple mechanisms after gastrectomy. The purpose of this study was to predict disease status after gastrectomy by analyzing diseases pattern that occur or change after gastrectomy.

Materials and Methods: A retrospective cohort study was conducted using nationwide claims data. Patients with gastric cancer who underwent gastrectomy or endoscopic resection were included in the study. Eighteen target diseases were selected and categorized based on their underlying mechanism. The incidence of each target disease was compared by dividing the study sample into those who underwent gastrectomy (cases) and those who underwent endoscopic resection for early gastric cancer (controls). The cases were matched with controls using propensity score matching. Thereafter, Cox proportional hazard models were used to evaluate intergroup differences in disease incidence after gastrectomy.

Results: A total of 97,634 patients who underwent gastrectomy (84,830) or endoscopic resection (12,804) were included. The incidence of cholecystitis (P<0.0001), pancreatitis (P=0.034), acute kidney injury (P=0.0083), anemia (P<0.0001), and inguinal hernia (P=0.0007) were higher after gastrectomy, while incidence of dyslipidemia (P<0.0001), vascular diseases (ischemic heart disease, stroke, and atherosclerosis; P<0.0001, P<0.0001, and P=0.0005), and Parkinson’s disease (P=0.0093) were lower after gastrectomy.

Conclusions: This study identifies diseases that may occur after gastrectomy in patients with gastric cancer.

Keywords: Gastrectomy; Stomach neoplasms; Big data; Incidence

INTRODUCTION

In 2014, the incidence of gastric cancer decreased to 35.8 per 100,000 people. However, an increase in its incidence has been observed since 2016, with the incidence of early gastric cancer (EGC) reaching approximately 76% in Korea [1]. The treatment of gastric cancer depends on the stage of the disease, and its fundamental treatment is gastrectomy.
The extent of gastrectomy is determined by the location, size, gross type, and stage of the tumor, and includes distal, proximal, total, and function-preserving gastrectomy [2]. Although there are some differences in results depending on the extent of resection, various changes in nutrition, metabolism, immunity, and psychological status of the patient occur through several mechanisms, such as changes in dietary habits, disorders in digestive function, changes in hormones, and changes in the anatomical structure after gastrectomy [3,4]. These changes are related to the occurrence, exacerbation, prevention, and improvement of various diseases. A recent study reported that the incidence of cardiovascular disease decreased after gastrectomy [5]. The study suggested that the risk of cardiovascular disease can be lowered due to positive effects, such as weight loss and decreased insulin resistance due to changes in nutritional intake after gastrectomy, and further showed the possibility of onco-metabolic surgery. Indeed, bariatric surgery can achieve these results and it is widely performed [6]. However, similar studies have reported that the incidence of osteoporosis, gall bladder stones, and pulmonary tuberculosis increases after gastrectomy [7-9].

Therefore, a well-planned study evaluating various diseases that may occur after gastrectomy is necessary to decrease cancer-unrelated deaths and improve the quality of life of survivors after gastrectomy. In this study, the occurrence, exacerbation, prevention, and improvement of 18 diseases that can occur after gastrectomy were analyzed using nationwide claims data.

MATERIALS AND METHODS

Study population
Data on disease incidence following gastrectomy were obtained from the National Health Insurance Services (NHIS) between 2002 and 2017. Inpatient and outpatient data of all populations was identified using the NHIS database owing to the single-payer healthcare insurance system in Korea. Cohorts were identified by the International Classification of Disease, Tenth Revision, Clinical Modification (ICD-10-CM) codes and pharmaceutical codes, along with procedure or operation codes. The gastrectomy group (case) included individuals diagnosed with the ICD-10 code C16 who had undergone procedural codes of gastrectomy, including subtotal or total gastrectomy, regardless of procedural codes of endoscopic resection (ER). The inclusion criteria included the following: other malignancies (ICD-10 codes C00–97, except C16), patients who received any systemic or radiation treatment, or recurrent gastric cancer. Recurrent stomach cancer was defined as patients who underwent total gastrectomy at least one year after subtotal gastrectomy or received additional systemic or radiation therapy at least one year after gastrectomy. The majority of the patients included were diagnosed with EGC. Lastly, patients suffering from a target disease or exposed to well-known risk factors for the target disease were excluded to reduce external effect bias. The control group included patients undergoing ER for gastric cancer to compensate for

Table 1. Definition and codes of each disease

| Disease                  | Variables | Definition                      | ICD-10 codes          | Procedure or operation (procedural codes) | Medication (pharmaceutical codes)               |
|--------------------------|-----------|---------------------------------|-----------------------|------------------------------------------|-------------------------------------------------|
| Gastrectomy (Case)       | Inclusion | Diagnosis and procedure         | C16                   | Gastrectomy                               | Platinum, fluorouracil, Tecan, taxel, Herceptin, nivolumab, ramucirumab |
|                          | Exclusion | Diagnosis or medication         | C00-97, except C16    |                                          |                                                 |
| EMR/ESD (Control)        | Inclusion | Diagnosis and procedure         | C16                   | EMR/ESD Gastroctomy                       | Platinum, fluorouracil, Tecan, taxel, Herceptin, nivolumab, ramucirumab |
|                          | Exclusion | Diagnosis or procedure or       | C00-97, except C16    |                                          |                                                 |

(continued to the next page)
| Disease | Variables | Definition | ICD-10 codes | Procedure or operation (procedural codes) | Medication (pharmaceutical codes) |
|---------|-----------|------------|--------------|------------------------------------------|----------------------------------|
| **Digestive disease** | | | | | |
| Cholecystitis | Inclusion | Diagnosis and procedure | K80-83 | Cholecystectomy, cholecystostomy | |
| | Additional matching | | | | |
| | Date of disease occurrence | | | | |
| | Washout period | 1 month (post-operative complication) | | | |
| Pancreatitis | Inclusion | Diagnosis and medication | K85, K86 | | Pancreatin, Biodiastase, Simethicone, mesilate, ulinastatin |
| | Additional matching | Diagnosis or procedure | E08-T1, E13 | | Pancreatectomy, pancreatic surgery, pancreas transplantation |
| | Date of disease occurrence | | | | |
| | Washout period | 1 month (post-operative complication) | | | |
| **Metabolic disease** | | | | | |
| Osteoporosis | Inclusion | Diagnosis and medication | M80-82 | | SERM, Bisphosphonate, STEAR, Calcitonin, Vitamin D |
| | Additional matching | Diagnosis or medication | E05, E21, N95, Z79 | | Estrogen |
| | Date of disease occurrence | Administration of first medication | | | |
| | Washout period | 3 months (metabolic change after gastrectomy) | | | |
| Type 2 diabetes mellitus | Inclusion | Diagnosis | E11 | | |
| | Additional matching | Diagnosis | I10, I15, I20-25, I63, E78 | | |
| | Date of disease occurrence | Administration of first medication | | | |
| | Washout period | 3 months (metabolic change after gastrectomy) | | | |
| Acute kidney injury | Inclusion | Diagnosis and procedure (duration less than 3 months) | N17 | Hemodialysis, peritoneal dialysis | |
| | Additional matching | Diagnosis | E08-T1, E13, I10, I15 | | |
| | Date of disease occurrence | Administration of first dialysis | | | |
| | Washout period | 3 months (metabolic change after gastrectomy) | | | |
| Dyslipidemia | Inclusion | Diagnosis and medication | E78 | | Acipimox, statin, cholestyramine, evolocumab, ezetimibe, fenofibrate, omega-3-acid, irbesartan |
| | Additional matching | Administration of first medication | | | |
| | Date of disease occurrence | 3 months (metabolic change after gastrectomy) | | | |
| Anemia (iron deficiency) | Inclusion | Diagnosis and medication | D50 | | Iron, ferric hydroxide, ferrous sulfate |
| | Additional matching | Administration of first medication | | | |
| | Date of disease occurrence | 3 months (metabolic change after gastrectomy) | | | |
| Anemia (vitamin B12 deficiency) | Inclusion | Diagnosis and medication | D51 | | Cobamide, cyanocobalamin |
| | Additional matching | Administration of first medication | | | |
| | Date of disease occurrence | 3 months (metabolic change after gastrectomy) | | | |

(continued to the next page)
## Table 1. (Continued) Definition and codes of each disease

| Disease | Variables | Definition | ICD-10 codes | Procedure or operation (procedural codes) | Medication (pharmaceutical codes) |
|---------|-----------|------------|--------------|-----------------------------------------|----------------------------------|
| **Vascular disease** | | | | | |
| Ischemic heart disease | Inclusion | Diagnosis | I20-25 | | |
| | Additional matching | Diagnosis | I10, I15, E08-11, E13, E78 | | |
| | Date of disease occurrence | Diagnosis day | | | |
| | Washout period | 3 months (metabolic change after gastrectomy) | | | |
| Stroke | Inclusion | Diagnosis | I63 | | |
| | Additional matching | Diagnosis | I10, I15, E08-11, E13, E78 | | |
| | Date of disease occurrence | Diagnosis day | | | |
| | Washout period | 3 months (metabolic change after gastrectomy) | | | |
| Atherosclerosis | Inclusion | Diagnosis | I70 | | |
| | Additional matching | Diagnosis | I10, I15, E08-11, E13, E78 | | |
| | Date of disease occurrence | Diagnosis day | | | |
| | Washout period | 3 months (metabolic change after gastrectomy) | | | |
| **Infectious disease** | | | | | |
| Infectious gastroenteritis | Inclusion | Diagnosis | A04, A05, A08, A09, K52 | Transplantation (liver, kidney, pancreas, heart, lung, small intestine, bone marrow) |
| | Additional matching | Diagnosis or procedure or medication | B20, Z94 | Immunoglobulin, immunosuppressant, steroid |
| | Date of disease occurrence | Diagnosis day | | | |
| | Washout period | 3 months (immunologic change after gastrectomy) | | | |
| Tuberculosis | Inclusion | Diagnosis | A15, A17-19 | Transplantation (liver, kidney, pancreas, heart, lung, small intestine, bone marrow) |
| | Additional matching | Diagnosis or procedure or medication | B20, E08-11, E13, N18, Z94 | Immunoglobulin, immunosuppressant, steroid |
| | Date of disease occurrence | Diagnosis day | | | |
| | Washout period | 3 months (immunologic change after gastrectomy) | | | |
| Syphilis | Inclusion | Diagnosis | A51-53 | Transplantation (liver, kidney, pancreas, heart, lung, small intestine, bone marrow) |
| | Additional matching | Diagnosis or procedure or medication | B20, Z94 | Immunoglobulin, immunosuppressant, steroid |
| | Date of disease occurrence | Diagnosis day | | | |
| | Washout period | 3 months (immunologic change after gastrectomy) | | | |
| Pneumonia | Inclusion | Diagnosis | J13-18, J20-22 | Transplantation (liver, kidney, pancreas, heart, lung, small intestine, bone marrow) |
| | Additional matching | Diagnosis or procedure or medication | B20, Z94 | Immunoglobulin, immunosuppressant, steroid |
| | Date of disease occurrence | Diagnosis day | | | |
| | Washout period | 3 months (immunologic change after gastrectomy) | | | |

(continued to the next page)
the effects of gastric cancer itself. The ER group (control) was similar to the gastrectomy group; however, only patients who underwent ER were included, while those who underwent additional gastrectomy were excluded (Table 1). The study was reviewed by the Institutional Review Board of the Gachon University Gil Medical Center and ethics approval was waived in compliance with governmental laws and regulations (protocol GFIRB2019-167), as well as informed consent since we only accessed de-identified data.

**Matching and washout period**

The following data were matched between the cohorts using the propensity score: year of treatment, sex, age, Charlson comorbidity index (CCI), residential area, and type of health coverage divided into two categories, health insurance and medical aid beneficiary, based on income level. Additionally, the well-known risk factors for each target disease were matched. Regarding the time required for changes in nutrition, metabolism, immunity, or psychological status following gastrectomy, a washout period was established for each disease, and events that occurred after that period were defined as disease occurrence. The washout periods were set to one month or three months based on the postoperative short-term complication period and rapid weight-loss period (Table 1) [10].

**Target diseases**

Each disease was categorized into one of five groups: digestive, metabolic, vascular, infectious, or other diseases. Digestive diseases included cholecystitis and pancreatitis; metabolic diseases included osteoporosis, type 2 diabetes mellitus (T2DM), acute kidney injury (AKI), dyslipidemia, iron deficiency anemia (IDA), and vitamin B12 deficiency anemia (VBDA); vascular diseases included ischemic heart disease (IHD), stroke, and atherosclerosis; and infectious diseases included infectious gastroenteritis, tuberculosis, syphilis, and pneumonia. Other target diseases included inguinal hernia, Parkinson’s disease, and dementia (Supplementary Fig. 1). We selected diseases that are easy to define, collect, and not likely to have a significant bias in the HIRA database among various diseases.

![Table 1](https://jgc-online.org)

**Table 1. (Continued) Definition and codes of each disease**

| Disease     | Variables                                      | Definition                                      | ICD-10 codes | Procedure or operation (procedural codes) | Medication (pharmaceutical codes) |
|-------------|-------------------------------------------------|-------------------------------------------------|--------------|-------------------------------------------|-----------------------------------|
| Inguinal hernia | Inclusion                                      | Diagnosis and procedure                        | K40          |                                            | Herniorrhaphy                     |
|             | Additional matching                             | Procedure day                                   |              |                                            |                                   |
|             | Date of disease occurrence                     |                                                 |              |                                            |                                   |
|             | Washout period                                 | 3 months (metabolic change after gastrectomy)  |              |                                            |                                   |
| Parkinson's disease | Inclusion                                      | Diagnosis                                      | G20          | I10, I15, I63, I70, E08-11, E13, E78     |                                   |
|             | Additional matching                             | Diagnosis day                                   |              |                                            |                                   |
|             | Date of disease occurrence                     | Diagnosis day                                   |              |                                            |                                   |
|             | Washout period                                 | 3 months (metabolic change after gastrectomy)  |              |                                            |                                   |
| Dementia     | Inclusion                                      | Diagnosis                                      | F01-03, G30  | I10, I15, I63, I70, E08-11, E13, E78     |                                   |
|             | Additional matching                             | Diagnosis                                      |              |                                            |                                   |
|             | Date of disease occurrence                     | Diagnosis day                                   |              |                                            |                                   |
|             | Washout period                                 | 3 months (metabolic change after gastrectomy)  |              |                                            |                                   |

ICD-10 = International Classification of Disease, Tenth Revision; EMR = endoscopic mucosal resection; ESD = endoscopic submucosal dissection.
known to change after gastrectomy or that may have a change in incidence. To evaluate the appropriateness of the model, diseases that are known to increase after gastrectomy, such as cholecystitis, were included.

**Statistical analyses**

After propensity score matching was performed, cumulative incidence using the Cox proportional hazard model was used to compensate for the difference between groups and to compare the incidence of diseases after gastric cancer surgery. The multivariate Cox model used variables showing significant differences that persisted even after propensity score matching for covariates. All statistical analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA) and R version 3.5.2 (R Foundation for Statistical Computing, Vienna, Austria) software. Drs. JHJ and HSS had full access to all study data and were responsible for data integrity and accuracy of data analysis.

**RESULTS**

A total of 97,634 patients who underwent gastrectomy (84,830) or ER (12,804) were included (Supplementary Fig. 2). Supplementary Tables 1-18 show the baseline characteristics and Cox regression analysis for each disease. Fig. 1 shows the forest plots of the adjusted hazard ratios (HRs) obtained from Cox regression analyses of each target disease.

**Digestive diseases**

In the multivariate Cox regression analysis, gastrectomy was an independent risk factor for cholecystitis (HR, 1.696; 95% confidence interval [CI], 1.291–2.228; P=0.0001) with a higher

![Forest plot](https://jgc-online.org/10.5230/jgc.2021.21.e29)
CCI compared to the other diseases. As a result of the cumulative incidence function (CIF), the occurrence of cholecystitis was significantly higher following gastrectomy than that after ER ($P<0.0001$; [Fig. 2A](#)). Gastrectomy was an independent risk factor for pancreatitis, along with a higher CCI and medical aid beneficiary compared to the other diseases (HR, 1.109; 95% CI, 1.015–1.213; $P=0.0228$), suggesting that the occurrence of pancreatitis was significantly higher following gastrectomy ($P=0.034$; [Fig. 2B](#); [Supplementary Tables 1](#) and [2](#)).

**Metabolic diseases**

Gastrectomy was not an independent risk or protective factor for osteoporosis or T2DM in the multivariate analysis. The risk factors for osteoporosis included female sex, older age, and higher CCI, whereas male sex, older age, higher CCI, and being a medical aid beneficiary were risk factors for T2DM. No significant difference was observed between gastrectomy and ER in CIF for osteoporosis and T2DM ($P=0.8026$, $P=0.3117$, respectively; [Fig. 3A](#) and [B](#); [Supplementary Tables 9–11](#)). Along with older age and higher CCI, gastrectomy was an independent risk factor (HR, 1.524; 95% CI, 1.004–2.315; $P=0.0481$) for AKI with dialysis, which was more frequently observed after gastrectomy ($P=0.0083$; [Fig. 3C](#)). In contrast, gastrectomy was an independent protective factor for dyslipidemia (HR, 0.461; 95% CI, 0.426–0.499; $P<0.0001$), along with male sex, younger age, and lower CCI, and occurred more frequently following ER than that after gastrectomy ($P<0.0001$; [Fig. 3D](#)). Gastrectomy was an independent risk factor for anemia, along with higher CCI and both IDA and VBDA (HR, 3.418; 95% CI, 3.135–3.726; $P<0.0001$; and HR, 9.313; 95% CI, 7.722–11.232; $P<0.0001$, respectively). A higher occurrence of both IDA and VBDA was observed following gastrectomy in terms of CIF ($P<0.0001$ and $P<0.0001$, respectively; [Fig. 3E](#) and [F](#); [Supplementary Tables 3–8](#)).

**Vascular diseases**

All three types of vascular diseases showed similar results, while gastrectomy was an independent protective factor for IHD, stroke, and atherosclerosis (HR, 0.692; 95% CI, 0.641–0.746; $P<0.0001$; HR, 0.713; 95% CI, 0.647–0.785; $P<0.0001$; and HR, 0.763; 95% CI, 0.688–0.847; $P<0.0001$, respectively), along with female sex, younger age, lower CCI, and health insurance. All vascular diseases occurred more frequently following ER in CIF ($P<0.0001$, $P<0.0001$, $P=0.0005$, respectively; [Fig. 4A](#), [B](#), and [C](#); [Supplementary Tables 9–11](#)).
Post-gastrectomy Disease Occurrence

**Fig. 3.** Cumulative incidence function based on the treatment modality in the category of metabolic diseases. (A) Osteoporosis, (B) Type 2 diabetes mellitus, (C) Acute kidney injury, (D) Dyslipidemia, (E) Iron deficiency anemia, and (F) Vitamin B12 deficiency anemia.

EMR = endoscopic mucosal resection; ESD = endoscopic submucosal dissection; CIF = cumulative incidence function; HR = hazard ratio.
Infectious diseases

Gastrectomy was an independent risk factor for infectious gastroenteritis (HR, 12.965; 95% CI, 11.446–14.685; P<0.0001). Infectious gastroenteritis was more frequently observed following gastrectomy in patients with CIF (P<0.0001; Fig. 5A). In contrast, gastrectomy was not a risk or protective factor for other infectious diseases, such as tuberculosis, syphilis, or pneumonia (P=0.9306, P=0.3859, and P=0.2027, respectively). There was no significant difference between gastrectomy and ER in CIF of these infectious diseases (P=0.8036, P=0.1992, and P=0.1062, respectively; Fig. 5B, C, and D; Supplementary Tables 12-15).

Other diseases

Gastrectomy was an independent risk factor for inguinal hernia (HR, 1.486; 95% CI, 1.237–1.785; P<0.0001), along with male sex and older age. Inguinal hernia occurred more frequently following gastrectomy than that after ER in CIF (P=0.0007; Fig. 6A). In contrast, gastrectomy was an independent protective factor for Parkinson’s disease (HR, 0.718; 95% CI, 0.575–0.897; P=0.0035), along with older age and higher CCI. The occurrence of Parkinson’s disease was high following ER in CIF (P=0.0093; Fig. 6B). However, gastrectomy was not an independent risk or protective factor for dementia (P=0.0583). However, female
We investigated the incidence of various diseases following gastrectomy in order to determine the anatomical, metabolic, nutritional, immunological, and psychological changes in gastric cancer survivors. In summary, the incidence of cholecystitis, pancreatitis, AKI, anemia, infectious gastroenteritis, and inguinal hernia increases, while the incidence of dyslipidemia, vascular diseases, and Parkinson’s disease decreases following gastrectomy. Cancer patients are generally more attentive to health management after diagnosis of cancer, and various changes, such as improvements in lifestyle and diet control, are typically implemented [11,12]. In addition, changes may occur due to the pathophysiology of cancer itself, which may act as a bias in the analyses performed in this study [13,14]. Therefore, to reduce this bias, patients diagnosed with gastric cancer who underwent ER alone, instead of gastrectomy, were included in the analysis to reduce this bias. Patients diagnosed with gastric cancer who underwent ER alone, instead of gastrectomy, were included in the analysis to reduce this bias.
of gastrectomy, were included in the control group. In addition, to eliminate the effects of chemotherapy and advanced gastric cancer, all patients who had been administered chemotherapeutic agents were excluded from the study. Although patients who received chemotherapy were excluded, patients who refused chemotherapy or who could not receive chemotherapy due to poor general conditions may have been included. In addition, there were patients who had only performed ER without gastrectomy in the ER group due to poor clinical status. However, we suspect that the number was very small, and it was more important to eliminate the effects of chemotherapy than to select patients that meet the definition of EGC. Therefore, the inclusion of a small number of patients with advanced gastric cancer is not expected to significantly affect the results of this study.

In addition to the effect of cancer, patients diagnosed with the target disease before gastrectomy or patients with well-known risk factors related to the target disease were excluded to reduce the external effect bias. In patients with well-known risk factors related to the target disease, the effect of the risk factors would be more significant than the impact of gastrectomy. Despite the possibility that well-known risk factors were not identified, it would not be many cases, and they were expected to exist to a similar degree in both groups. Hence,
we suspect that undetected risk factors were not a significant bias in this study, which was performed with a sufficient number of cases. Therefore, it can be said that the results of this study depict the effects of gastrectomy on gastric cancer survivors.

In gastric cancer, the extent of gastrectomy is determined based on tumor location [2,15]. As a standard therapy, subtotal or total gastrectomy is performed, and 60%–100% of the stomach is removed during this process [16,17]. In the case of subtotal gastrectomy, the antrum and body are removed, and in this process, parietal, mucus, chief, G-, D-, and endocrine cells are removed [18,19]. As a result, acid secretion is reduced along with gastric secretory products, such as pepsin, prostaglandin, histamine, gastrin, somatostatin, intrinsic factor, and ghrelin [20-22]. IDA is a common post-gastrectomy syndrome resulting from decreased iron absorption due to impaired acid secretion following gastrectomy [23,24]. In this study, the HR of gastrectomy for IDA was 3.418. In addition, decreased intrinsic factors cause impairment of vitamin B12 absorption, which, in turn, causes VBDA [25]. In this study, the HR of gastrectomy for VBDA was 9.313. These two types of anemia (IDA and VBDA) are the most common post-gastrectomy syndromes, suggesting that the cohort for this study was properly selected [26]. In addition, this study is the first large-scale study conducted to identify the effect of gastrectomy on IDA or VBDA, compared to the effects of ER on these two conditions.

Post-gastrectomy metabolic disturbance is one of the most common causes of osteoporosis [8,27]. However, in this study, there was no significant difference in the incidence of osteoporosis between the gastrectomy and ER groups. This could be attributed to a lack of interest in osteoporosis among patients with cancer. In Korea, bone mineral densitometry is covered by national insurance for men over 70 years of age and women over 65 years of age. However, similar to patients, physicians are often less interested in osteoporosis, a relatively mild disease and, therefore, do not perform appropriate evaluations such as bone mineral densitometry. Breast cancer and post-menopausal status are closely related to osteoporosis, and most studies on osteoporosis in cancer patients are focused on these patients [28]. However, gastrectomy is also a significant risk factor for the occurrence of osteoporosis; therefore, the use of appropriate examinations by physicians for the early diagnosis of osteoporosis is essential for treating gastric cancer. Similarly, metabolic disturbances can cause body shape changes, such as abdominal wall loosening. Advancing age and lower body mass index are thought to be risk factors for inguinal hernia [29]; indeed, abdominal wall loosening, which is caused by aging, elevated intra-abdominal pressure, and decreased muscle strength, may be the reason for the occurrence of these risk factors [30]. In this study, gastrectomy showed an HR of 1.486 for inguinal hernia. We assumed that this was a result of body shape changes following gastrectomy. Therefore, proper follow-up and evaluation of inguinal hernia after gastrectomy are necessary. It is noteworthy that this is the first study to report the relationship between gastrectomy and inguinal hernia.

Although peri-gastric anatomy changes following gastrectomy for gastric cancer depend on the extent of gastrectomy and reconstruction methods, in the case of distal gastrectomy, the pylorus is removed, and the remnant stomach is Anastomosed to the duodenum or jejunum. Indeed, in a previous study, the storage function of the remnant stomach decreased and the function of the antrum disappeared [21]. Also, after distal gastrectomy, there are various reconstruction methods, such as Billroth-I, Billroth-II, or Roux-en-Y reconstruction, and various changes such as bypassing the duodenum or changing the peristaltic direction, appear in addition to weight loss according to the reconstruction methods. Although there is
debate about the advantages and disadvantages of each anastomosis method, the anatomical changes are manifested by dumping syndrome, gastric stasis, and malabsorption [23]. These anatomical changes have been reported to be effective in metabolic surgery, specifically bariatric surgery, and are widely used as treatment for various metabolic diseases, such as T2DM and dyslipidemia [6]. The theory of metabolic surgery has been verified in various studies related to bariatric surgery, and research on onco-metabolic surgery is also underway [31,32]. In this study, the HRs of IHD, stroke, and atherosclerosis were 0.692, 0.713, and 0.763, respectively, after gastrectomy. In addition, the HR of dyslipidemia, which is a significant risk factor for IHD, stroke, and atherosclerosis, was 0.461 after gastrectomy. These results suggest that metabolic disturbances following gastrectomy reduce the incidence of dyslipidemia and further reduce the overall incidence of vascular disease. Several studies have reported that gastrectomy reduces the incidence of IHD [5]. In contrast, regarding T2DM, the main target of onco-metabolic surgery, no significant difference was observed between the gastrectomy and ER groups in this study. In a previous study, metabolic surgery was performed for patients with severe T2DM requiring insulin administration or with HbA1c >6.0 [6]. However, the definition of T2DM in this study did not account for the severity of T2DM, since it was intended for cases with ICD-10 diagnostic codes. Therefore, cases of mild T2DM were included, in which medication was not administered and diet control alone was followed. In addition, while previous metabolic surgery-related studies have focused on the treatment of T2DM, this study focused on the incidence of T2DM [32]. This is thought to have caused differences in our results compared with previous studies. In the case of renal diseases, chronic kidney disease and AKI were classified based on whether the duration of dialysis was greater, equal to, or less than three months [33]. The incidence of AKI following gastrectomy increased, with an HR of 1.524. Although the cause and timing of AKI are not clear in this study, dehydration may play a causal role, as it is common after gastrectomy [34]. In particular, intestinal obstruction may result in severe dehydration, which is a common complication after gastrectomy [35].

Previous studies have reported that malnutrition after gastrectomy causes immune disturbances [36,37]. Therefore, the incidence of infectious diseases was analyzed to determine whether malnutrition following gastrectomy could indeed cause an immune disturbance in the real world. As a result, infectious gastroenteritis rapidly increased after gastrectomy. However, no significant difference between the groups was observed for other infectious diseases, such as tuberculosis, syphilis, and pneumonia. These results suggest that immunologic changes may occur due to malnutrition following gastrectomy; however, in our study, they were not severe and could be managed relatively well with appropriate supportive care. In addition, infectious gastroenteritis was thought to be caused by increased exposure to infectious sources, such as food poisoning, owing to decreased acid secretion, rather than immune disturbance after gastrectomy [22]. Although diseases, such as hepatitis A virus infection, acquired immunodeficiency syndrome, and herpes infection, could not be analyzed due to their extremely low incidence, this study is the first to analyze immunologic changes in patients with gastric cancer after gastrectomy.

Lymph node (LN) dissection is important in gastric cancer [2]. During supra-pancreatic LN dissection, pancreatic compression is performed, which can manifest as postoperative pancreatitis or pancreatic fistula [38]. Most studies on postoperative pancreatitis have focused on short-term outcomes, and there is a lack of evidence on the long-term outcomes of pancreatitis and pancreatic fistula [39]. Occasionally, there is a case in which serum amylase increases without symptoms, and medication is administered during the follow-
up process after gastrectomy. In this study, the incidence of pancreatitis was higher in the gastrectomy group, with an HR of 1.109. Since the definition of the occurrence of pancreatitis involved simply a diagnosis with a medication code, asymptomatic pancreatitis was also included. Thus, a follow-up study to analyze the long-term outcomes of asymptomatic pancreatitis is needed to validate our findings and for clinical significance.

LN station #1 dissection is necessary for standard radical gastrectomy, and truncal vagotomy must be performed during this process [15]. Truncal vagotomy is not performed during pylorus-preserving gastrectomy; however, the latter is a rare procedure [40]. When vagotomy is performed, cholestasis occurs owing to a decrease in the motility of the gall bladder, and, subsequently, the incidence of gallstones and cholecystitis increases [7]. In this study, the incidence of cholecystitis increased with an HR of 1.696 following gastrectomy. This result is consistent with the PEGASUS-D trial results and suggests that proper follow-up and evaluation of cholecystitis after gastrectomy are necessary [41]. Parkinson’s disease is one of the diseases associated with vagotomy [42]. The “dual hit” hypothesis is that a neurotropic pathogen enters the brain via the nasal or gastric route through the vagal nerve. Thus, truncal vagotomy may lower the incidence of PD [43]. In this study, gastrectomy reduced Parkinson’s disease, with an HR of 0.718; also, this is the first study to analyze the association between vagotomy performed during gastrectomy for gastric cancer and Parkinson’s disease. Dementia is either vascular or caused by Lewy bodies or atrophy of the brain [44]. We analyzed whether the incidence of dementia was affected following gastrectomy. However, no significant difference was observed between the groups, with a trend of a slightly increased incidence of dementia after gastrectomy. This may be due to various reasons, such as malnutrition or heterogeneity of dementia itself, and warrants further study.

This study has several limitations. First, we evaluated a large dataset collected from a single nation. However, along with Japan, Korea has the highest incidence of gastric cancer worldwide with many survivors, owing to its very high survival rate [45]. Therefore, Korea is considered the most appropriate area for conducting this study. Also, we were unable to explain the causal relationship and mechanism between gastrectomy and the respective diseases. Additionally, detailed individual data and cancer stages were not included. This is a common limitation observed while evaluating large datasets, such as the HIRA database, and appropriate interpretation is required using existing knowledge. Additionally, an adequate analysis was not possible for some diseases, as they had a very low incidence rate. These diseases require additional basic research and animal studies. Also, there is insufficient evidence for the washout period. However, based on the fact that the postoperative short-term surgical outcome had been set at one month in the general study and the body mass index rapidly decreased and started to recover within six months after gastrectomy, the washout period was set to one month and three months, respectively [10].

In this study, 18 diseases that can occur after gastrectomy for gastric cancer were investigated. For some diseases, previously known information could be verified, and the value of HR could be confirmed, while for other diseases, a possible new association with gastrectomy was identified. To investigate the mechanism of these diseases, specific studies on each disease are needed. The results of this study reveal the specific diseases that physicians should focus on while treating patients after gastrectomy. In addition, our study results can serve to provide the basis for the appropriate implementation and insurance coverage for the examination of these diseases.
ACKNOWLEDGMENTS

The authors, Ho Seok Seo, Yewon Na, and Jaehun Jung, have no conflicts of interest or financial ties to disclose.

SUPPLEMENTARY MATERIALS

Supplementary Table 1
Baseline characteristics and COX regression analysis for cholecystitis
Click here to view

Supplementary Table 2
Baseline characteristics and COX regression analysis for pancreatitis
Click here to view

Supplementary Table 3
Baseline characteristics and COX regression analysis for osteoporosis
Click here to view

Supplementary Table 4
Baseline characteristics and COX regression analysis for type 2 DM
Click here to view

Supplementary Table 5
Baseline characteristics and COX regression analysis for acute kidney injury
Click here to view

Supplementary Table 6
Baseline characteristics and COX regression analysis for dyslipidemia
Click here to view

Supplementary Table 7
Baseline characteristics and COX regression analysis for anemia (iron deficiency)
Click here to view

Supplementary Table 8
Baseline characteristics and COX regression analysis for anemia (vitamin B12 deficiency)
Click here to view
Supplementary Table 9
Baseline characteristics and COX regression analysis for ischemic heart disease
Click here to view

Supplementary Table 10
Baseline characteristics and COX regression analysis for stroke
Click here to view

Supplementary Table 11
Baseline characteristics and COX regression analysis for atherosclerosis
Click here to view

Supplementary Table 12
Baseline characteristics and COX regression analysis for infectious gastroenteritis
Click here to view

Supplementary Table 13
Baseline characteristics and COX regression analysis for tuberculosis
Click here to view

Supplementary Table 14
Baseline characteristics and COX regression analysis for syphilis
Click here to view

Supplementary Table 15
Baseline characteristics and COX regression analysis for pneumonia
Click here to view

Supplementary Table 16
Baseline characteristics and COX regression analysis for inguinal hernia
Click here to view

Supplementary Table 17
Baseline characteristics and COX regression analysis for Parkinson’s disease
Click here to view

Supplementary Table 18
Baseline characteristics and COX regression analysis for dementia
Click here to view
Supplementary Fig. 1
Five categories and eighteen diseases.

Click here to view

Supplementary Fig. 2
Flowsheet of the cohort.

Click here to view

REFERENCES

1. Hong S, Won YJ, Park YR, Jung KW, Kong HJ, Lee ES, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2017. Cancer Res Treat 2020;52:335-350.
   PUBMED | CROSSREF

2. Guideline Committee of the Korean Gastric Cancer Association (KGCA), Development Working Group & Review Panel. Korean Practice Guideline for Gastric Cancer 2018: an evidence-based, multi-disciplinary approach. J Gastric Cancer 2019;19:1-48.
   PUBMED | CROSSREF

3. Lee SS, Yu W, Chung HY, Kwon OK, Lee WK. Using quality of life scales with nutritional relevance after gastrectomy: a challenge for providing personalized treatment. J Gastric Cancer 2017;17:342-353.
   PUBMED | CROSSREF

4. Pyo JH, Lee H, Min BH, Lee JH, Choi MG, Lee JH, et al. Long-term outcome of endoscopic resection vs. surgery for early gastric cancer: a non-inferiority-matched cohort study. Am J Gastroenterol 2016;111:240-249.
   PUBMED | CROSSREF

5. Shin DW, Suh B, Park Y, Lim H, Suh YS, Yun JM, et al. Risk of coronary heart disease and ischemic stroke incidence in gastric cancer survivors: a nationwide study in Korea. Ann Surg Oncol 2018;25:3248-3256.
   PUBMED | CROSSREF

6. Schauer PR, Bhatt DL, Kirwan JP, Wolski K, Aminian A, Brethauer SA, et al. Bariatric surgery versus intensive medical therapy for diabetes - 5-year outcomes. N Engl J Med 2017;376:641-651.
   PUBMED | CROSSREF

7. Kim SY, Bang WJ, Lim H, Lim MS, Kim M, Choi HG. Increased risk of gallstones after gastrectomy: A longitudinal follow-up study using a national sample cohort in Korea. Medicine (Baltimore) 2019;98:e15932.
   PUBMED | CROSSREF

8. Iki M, Fujita Y, Kouda K, Yura A, Tachiki T, Tamaki T, et al. Increased risk of osteoporotic fracture in community-dwelling elderly men 20 or more years after gastrectomy: the Fujiwara-kyo Osteoporosis Risk in Men (FORMEN) Cohort Study. Bone 2019;127:250-259.
   PUBMED | CROSSREF

9. Cheng KC, Liao KF, Lin CL, Lai SW. Gastrectomy correlates with increased risk of pulmonary tuberculosis: a population-based cohort study in Taiwan. Medicine (Baltimore) 2018;97:e11388.
   PUBMED | CROSSREF

10. Seo HS, Jung YJ, Kim JH, Park CH, Kim IH, Lee HH. Long-term nutritional outcomes of near-total gastrectomy in gastric cancer treatment: a comparison with total gastrectomy using propensity score matching analysis. J Gastric Cancer 2018;18:189-199.
    PUBMED | CROSSREF

11. Stacey FG, James EL, Chapman K, Courneya KS, Lubans DR. A systematic review and meta-analysis of social cognitive theory-based physical activity and/or nutrition behavior change interventions for cancer survivors. J Cancer Surviv 2015;9:305-338.
    PUBMED | CROSSREF

12. Kerr J, Anderson C, Lippman SM. Physical activity, sedentary behaviour, diet, and cancer: an update and emerging new evidence. Lancet Oncol 2017;18:e457-e471.
    PUBMED | CROSSREF

13. Kuwada K, Kuroda S, Kikuchi S, Yoshida R, Nishizaki M, Kagawa S, et al. Clinical impact of sarcopenia on gastric cancer. Anticancer Res 2019;39:2241-2249.
    PUBMED | CROSSREF

https://doi.org/10.5230/jgc.2021.21.e29
14. Wang K, Zhao XH, Liu J, Zhang R, Li JP. Nervous system and gastric cancer. Biochim Biophys Acta Rev Cancer 2020;1873:188313.  
PUBMED | CROSSREF

15. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer 2017;20:1-19.  
PUBMED | CROSSREF

16. Santoro R, Ettorre GM, Santoro E. Subtotal gastrectomy for gastric cancer. World J Gastroenterol 2014;20:13667-13680.  
PUBMED | CROSSREF

17. Lee JH, Kim YI. Which is the optimal extent of resection in middle third gastric cancer between total gastrectomy and subtotal gastrectomy? J Gastric Cancer 2010;10:226-233.  
PUBMED | CROSSREF

18. Owen DA. Normal histology of the stomach. Am J Surg Pathol 1986;10:48-61.  
PUBMED | CROSSREF

19. Oh HJ, Choi MG, Park JM, Song KY, Yoo HM. Acid secretion and its relationship to esophageal reflux symptom in patients with subtotal gastrectomy. Dig Dis Sci 2018;63:703-712.  
PUBMED | CROSSREF

20. Koopmans HS. A stomach hormone that inhibits food intake. J Auton Nerv Syst 1983;9:157-171.  
PUBMED | CROSSREF

21. Johnson LR. Functional development of the stomach. Annu Rev Physiol 1985;47:199-215.  
PUBMED | CROSSREF

22. Lundell L. Acid secretion and gastric surgery. Dig Dis 2011;29:487-490.  
PUBMED | CROSSREF

23. Bolton JS, Conway WC 2nd. Postgastrectomy syndromes. Surg Clin North Am 2011;91:1105-1122.  
PUBMED | CROSSREF

24. Jun JH, Yoo JE, Lee JA, Kim YS, Sunwoo S, Kim BS, et al. Anemia after gastrectomy in long-term survivors of gastric cancer: a retrospective cohort study. Int J Surg 2016;28:162-168.  
PUBMED | CROSSREF

25. Lim CH, Kim SW, Kim WC, Kim JS, Cho YK, Park JM, et al. Anemia after gastrectomy for early gastric cancer: long-term follow-up observational study. World J Gastroenterol 2012;18:6114-6119.  
PUBMED | CROSSREF

26. Kwon Y, Kim HJ, Lo Menzo E, Park S, Szomstein S, Rosenthal RJ. Anemia, iron and vitamin B12 deficiencies after sleeve gastrectomy compared to Roux-en-Y gastric bypass: a meta-analysis. Surg Obes Relat Dis 2014;10:589-597.  
PUBMED | CROSSREF

27. Yoo SH, Lee JA, Kang SY, Kim YS, Sunwoo S, Kim BS, et al. Risk of osteoporosis after gastrectomy in long-term gastric cancer survivors. Gastric Cancer 2018;21:720-727.  
PUBMED | CROSSREF

28. Muhammad A, Mada SB, Malami I, Forcados GE, Erukainure OL, Sani H, et al. Postmenopausal osteoporosis and breast cancer: The biochemical links and beneficial effects of functional foods. Biomed Pharmacother 2018;107:571-582.  
PUBMED | CROSSREF

29. de Goede B, Timmermans L, van Kempen BJ, van Rooij FJ, Kazemier G, Lange JF, et al. Risk factors for inguinal hernia in middle-aged and elderly men: results from the Rotterdam Study. Surgery 2015;157:540-546.  
PUBMED | CROSSREF

30. Ruhl CE, Everhart JE. Risk factors for inguinal hernia among adults in the US population. Am J Epidemiol 2007;165:1154-1161.  
PUBMED | CROSSREF

31. Peterli R, Wölnerhanssen BK, Peters T, Vetter D, Kröll D, Borbély Y, et al. Effect of laparoscopic sleeve gastrectomy vs laparoscopic Roux-en-Y gastric bypass on weight loss in patients with morbid obesity: the SM-BOSS randomized clinical trial. JAMA 2018;319:255-265.  
PUBMED | CROSSREF

32. Lee TH, Lee CM, Park S, Jung DH, Jang YJ, Kim JH, et al. Long-term follow-up for type 2 diabetes mellitus after gastrectomy in non-morbidly obese patients with gastric cancer: the legitimacy of onco-metabolic surgery. J Gastric Cancer 2017;17:283-294.  
PUBMED | CROSSREF

33. McMahon GM, Preis SR, Hwang SJ, Fox CS. Mid-adulthood risk factor profiles for CKD. J Am Soc Nephrol 2014;25:2633-2641.  
PUBMED | CROSSREF
34. Li SS, Costantino CL, Mullen JT. Morbidity and mortality of total gastrectomy: a comprehensive analysis of 90-day outcomes. J Gastrointest Surg 2019;23:1340-1348.
35. Rami Reddy SR, Cappell MS. A systematic review of the clinical presentation, diagnosis, and treatment of small bowel obstruction. Curr Gastroenterol Rep 2017;19:28.
36. Wu JM, Lin MT. Effects of specific nutrients on immune modulation in patients with gastrectomy. Ann Gastroenterol Surg 2019;4:14-20.
37. Díaz Rodríguez V, Barroso de Pinho N, Abdelhay E, Viola JP, Correia MI, Brun Martucci R. Nutrition and immune-modulatory intervention in surgical patients with gastric cancer. Nutr Clin Pract 2017;32:122-129.
38. Hiki N, Honda M, Etoh T, Yoshida K, Kodera Y, Kakeji Y, et al. Higher incidence of pancreatic fistula in laparoscopic gastrectomy. Real-world evidence from a nationwide prospective cohort study. Gastric Cancer 2018;21:162-170.
39. Seo HS, Shim JH, Jeon HM, Park CH, Song KY. Postoperative pancreatic fistula after robot distal gastrectomy. J Surg Res 2015;194:361-366.
40. Oh SY, Lee HJ, Yang HK. Pylorus-preserving gastrectomy for gastric cancer. J Gastric Cancer 2016;16:63-71.
41. Lee SH, Jang DK, Yoo MW, Hwang SH, Ryu SY, Kwon OK, et al. Efficacy and safety of ursodeoxycholic acid for the prevention of gallstone formation after gastrectomy in patients with gastric cancer: the PEGASUS-D randomized clinical trial. JAMA Surg 2020;155:703-711.
42. Svensson E, Horváth-Puhó E, Thomsen RW, Djurhuus JC, Pedersen L, Borghammer P, et al. Vagotomy and subsequent risk of Parkinson’s disease. Ann Neurol 2015;78:522-529.
43. Hawkes CH, Del Tredici K, Braak H. Parkinson’s disease: the dual hit theory revisited. Ann N Y Acad Sci 2009;1170:615-622.
44. Raz L, Knoefel J, Bhaskar K. The neuropathology and cerebrovascular mechanisms of dementia. J Cereb Blood Flow Metab 2016;36:172-186.
45. Jung KW, Won YI, Hong HI, Lee ES. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2016. Cancer Res Treat 2019;51:417-430.